A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.

Authors :: Barve, Minal A.
Tolcher, Anthony W.
Carvajal, Richard D.
Izar, Benjamin
El-Khoueiry, Anthony B.
Hanna, Diana L.
Tarhini, Ahmad A.
Whitman, Eric D.
Bhatia, Shailender
Davar, Diwakar
Lutzky, Jose
Taylor, Matthew H.
Tello, Monique
Rosenthal, Katherine
Danielyan, Anna
Yip, Wai Ki
Song, James
Savitsky, David
Chand, Dhan
Grossman, Joseph Elan
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p2524-2524, 1p
Publication Year :: 2023

Full Text Access

Tools